Verastem stock
VSTMNASDAQVerastem, Inc., HealthcareISIN US92337C2035
42Score 42 out of 100, Weak
Price and trend
77 / 100
Price history
+7.6% in one yearThe chart shows daily closes over 15 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 45% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 35).
The price is 15% below its 52-week high. Largest decline in 15 years: 99% (July 2013 to August 2024).
Chart figures for advanced users
- SMA 50$8.47
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$6.28
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)35
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.45
- The lowest closing price of the last twelve months.
- Resistance$10.64
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Verastem, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.15B, is number 183 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $30.91M (up 209.1% year on year) and a loss of $209.47M.
- For fiscal 2026, analysts expect on average revenue of $113.48M (up 267.1%) and adjusted earnings per share of −$1.63.
Show more
- MEQIRI Score 42 out of 100 (Weak): rank 528 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $172.8M, financial debt $122.12M.
Weaknesses
- DilutionShare count up 442% since 2020.Capital allocation 24
- High debtDebt 12.09 times equity (latest quarter), Biotechnology median 0.09.Stability 24
- Loss-makingLoss of $178.9M over the last 12 months.Fundamentals 20
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 209% on the prior year. Revenue has grown strongly since 2024, at around 209% per year. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 83%, operating −550%, net −678%. Last 12 months: net −100%. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 3 Mar 2027in 111 days
- Last reported
- 5 Nov 2026EPS reported −$0.74 (expected −$0.47)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 7.0% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$1.63+1.7%
- Revenue
- $113.48M−2.4%
- Earnings per share
- −$1.57−7.0%
- Revenue
- $159.1M−6.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +14.8%The company still expects the LGSOC business to become self-sustaining by the end of 2026 and roughly flat quarterly SG&A expenses.
“Also, as we shared previously, we continue to expect the LGSOC business will become self-sustaining by the end of 2026, meaning that commercial revenue will support both the ongoing commercial organization and the existing avutometinib and defactinib development franchise.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $498,284 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Paterson DanSale
3 Nov 2026, President and CEO
- Shares
- 1,299
- Price
- $9.60
- Value
- $12,470
- Paterson DanSale
1 Oct 2026, President and CEO
- Shares
- 44,121
- Price
- $8.00
- Value
- $352,968
- Calkins DanielSale
1 Oct 2026, Chief Financial Officer
- Shares
- 2,566
- Price
- $8.00
- Value
- $20,528
Show 4 more
- Calkins DanielSale
21 Sept 2026, Chief Financial Officer
- Shares
- 55
- Price
- $7.70
- Value
- $424
- Paterson DanSale
3 Aug 2026, President and CEO
- Shares
- 1,302
- Price
- $5.81
- Value
- $7,565
- Paterson DanSale
22 Jun 2026, President and CEO
- Shares
- 20,871
- Price
- $4.18
- Value
- $87,241
- Calkins DanielSale
22 Jun 2026, Chief Financial Officer
- Shares
- 4,089
- Price
- $4.18
- Value
- $17,089
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Verastem
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 42
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- MedinCellMEDCL.PA $1.19B48
- SpyGlass PharmaSGP $1.17B46
- MoonLake ImmunotherapeuticsMLTX $1.15B36
- Solid BiosciencesSLDB $1.15B42
- Seaport TherapeuticsSPTX $1.14B47
- Vor BiopharmaVOR $1.09B46
- InventivaIVA.PA $1.07B31
- Corvus PharmaceuticalsCRVS $1.06B38
ETFs that hold Verastem
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2013)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.